DEUCRAVACITINIB

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H22N8O3
Molecular Weight	425.459
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[2H]C([2H])([2H])NC(=O)C1=C(NC2=CC=CC(C3=NN(C)C=N3)=C2OC)C=C(NC(=O)C4CC4)N=N1

InChI

InChIKey=BZZKEPGENYLQSC-FIBGUPNXSA-N

InChI=1S/C20H22N8O3/c1-21-20(30)16-14(9-15(25-26-16)24-19(29)11-7-8-11)23-13-6-4-5-12(17(13)31-3)18-22-10-28(2)27-18/h4-6,9-11H,7-8H2,1-3H3,(H,21,30)(H2,23,24,25,29)/i1D3

HIDE SMILES / InChI

Approval Year

C_max

Value	Dose	Co-administered	Analyte	Population
3.33 ng/mL CLINICAL TRIAL https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13435	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:		BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
19.6 ng/mL CLINICAL TRIAL https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13435	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:		BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
102 ng/mL CLINICAL TRIAL https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13435	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
185 ng/mL CLINICAL TRIAL https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13435	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
410 ng/mL CLINICAL TRIAL https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13435	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
15.2 ng/mL CLINICAL TRIAL https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13435	2 mg 2 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:		BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
49.6 ng/mL CLINICAL TRIAL https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13435	4 mg 2 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered:		BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
70 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/36325947/	6 mg 2 times / day multiple, oral dose: 6 mg route of administration: Oral experiment type: MULTIPLE co-administered:		BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
126 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/36325947/	6 mg 2 times / day multiple, oral dose: 6 mg route of administration: Oral experiment type: MULTIPLE co-administered:		BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
117 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/36325947/	6 mg 2 times / day multiple, oral dose: 6 mg route of administration: Oral experiment type: MULTIPLE co-administered:		BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
41.7 ng/mL CLINICAL TRIAL https://academic.oup.com/ecco-jcc/article/13/Supplement_1/S277/5301077	4 mg 1 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered:		BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
48.2 ng/mL CLINICAL TRIAL https://academic.oup.com/ecco-jcc/article/13/Supplement_1/S277/5301077	4 mg 1 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered: Cyclosporine A	Cyclosporine A	BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
45 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214958s000lbl.pdf	6 mg 1 times / day multiple, oral dose: 6 mg route of administration: Oral experiment type: MULTIPLE co-administered:		DEUCRAVACITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
28.2 ng × h/mL CLINICAL TRIAL https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13435	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:		BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
143 ng × h/mL CLINICAL TRIAL https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13435	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:		BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
752 ng × h/mL CLINICAL TRIAL https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13435	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1175 ng × h/mL CLINICAL TRIAL https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13435	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3460 ng × h/mL CLINICAL TRIAL https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13435	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
90.5 ng × h/mL CLINICAL TRIAL https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13435	2 mg 2 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:		BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
315 ng × h/mL CLINICAL TRIAL https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13435	4 mg 2 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered:		BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
429 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/36325947/	6 mg 2 times / day multiple, oral dose: 6 mg route of administration: Oral experiment type: MULTIPLE co-administered:		BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
789 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/36325947/	6 mg 2 times / day multiple, oral dose: 6 mg route of administration: Oral experiment type: MULTIPLE co-administered:		BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
803 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/36325947/	6 mg 2 times / day multiple, oral dose: 6 mg route of administration: Oral experiment type: MULTIPLE co-administered:		BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
359 ng × h/mL CLINICAL TRIAL https://academic.oup.com/ecco-jcc/article/13/Supplement_1/S277/5301077	4 mg 1 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered:		BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
463 ng × h/mL CLINICAL TRIAL https://academic.oup.com/ecco-jcc/article/13/Supplement_1/S277/5301077	4 mg 1 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered: Cyclosporine A	Cyclosporine A	BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
473 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214958s000lbl.pdf	6 mg 1 times / day multiple, oral dose: 6 mg route of administration: Oral experiment type: MULTIPLE co-administered:		DEUCRAVACITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
7.93 h CLINICAL TRIAL https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13435	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
11 h CLINICAL TRIAL https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13435	3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered:	BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
9.87 h CLINICAL TRIAL https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13435	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
14.9 h CLINICAL TRIAL https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13435	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
15 h CLINICAL TRIAL https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13435	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
8.63 h CLINICAL TRIAL https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13435	2 mg 2 times / day multiple, oral dose: 2 mg route of administration: Oral experiment type: MULTIPLE co-administered:	BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
10.7 h CLINICAL TRIAL https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.13435	4 mg 2 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered:	BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
9.12 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/36325947/	6 mg 2 times / day multiple, oral dose: 6 mg route of administration: Oral experiment type: MULTIPLE co-administered:	BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
7.46 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/36325947/	6 mg 2 times / day multiple, oral dose: 6 mg route of administration: Oral experiment type: MULTIPLE co-administered:	BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
13.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/36325947/	6 mg 2 times / day multiple, oral dose: 6 mg route of administration: Oral experiment type: MULTIPLE co-administered:	BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
10 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214958s000lbl.pdf	6 mg 1 times / day multiple, oral dose: 6 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DEUCRAVACITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Analyte	Population
18% EXPERIMENT https://link.springer.com/article/10.1007/s40265-022-01796-y	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
10% EXPERIMENT https://link.springer.com/article/10.1007/s40265-022-01796-y	1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered:	BMS-986165 plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
14% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214958s000lbl.pdf	6 mg 1 times / day multiple, oral dose: 6 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DEUCRAVACITINIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Name

Type

Language

DEUCRAVACITINIB

Official Name

English

SOTYKTU

Preferred Name

English

6-((CYCLOPROPYLCARBONYL)AMINO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(2H3)METHYL-3-PYRIDAZINE-CARBOXAMIDE

Systematic Name

English

Deucravacitinib [WHO-DD]

Common Name

English

DEUCRAVACITINIB [JAN]

Common Name

English

DEUCRAVACITINIB [USAN]

Common Name

English

3-PYRIDAZINECARBOXAMIDE, 6-((CYCLOPROPYLCARBONYL)AMINO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3)-

Systematic Name

English

BMS-986165

Common Name

English

deucravacitinib [INN]

Common Name

English

Code System Code Type Description

FDA UNII

N0A21N6RAU